JP Morgan Chase
ABUS icon

JP Morgan Chase’s Arbutus Biopharma ABUS Stock Holding History

JP Morgan Chase’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-129,000
Closed -$462K – 5739
2019
Q1 		$462K Buy
129,000
+54,000
+72% +$207K ﹤0.01% 4247
2018
Q4 		$287K Sell
75,000
-67,000
-47% -$330K ﹤0.01% 4418
2018
Q3 		$1.34M Buy
+142,000
New +$1.41M ﹤0.01% 3725

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's ABUS Position: Q2 2026 in Review

JP Morgan Chase increased its Arbutus Biopharma (ABUS) stake by 13% in Q2 2026, buying an estimated $49.1K and bringing the position to 98,224 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #5170.

JP Morgan Chase first reported a position in ABUS in Q2 2015 and has held it in 38 quarters since. The position peaked at $2.93M in Q4 2024. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • JP Morgan Chase held 98,224 shares of Arbutus Biopharma worth $460K as of Q2 2026.
  • JP Morgan Chase bought 11,175 Arbutus Biopharma shares in Q2 2026, an estimated $49.1K.
  • Arbutus Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5170 holding.
  • JP Morgan Chase first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 38 quarters since.
  • JP Morgan Chase's Arbutus Biopharma position peaked at $2.93M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.